(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Merz visit highlights new strategic, and strained, Germany-Israel bond - 2Illustrations Gained from a Crosscountry Excursion
- 3James Webb Space Telescope spies mysterious high-energy radiation in star nursery
- 4My prescription costs what?! Pharmacists offer tips that could reduce your out-of-pocket drug costs
- 5Egypt's cafés and shops forced to close early due to Iran war
- The Best Design Bloggers for Style Motivation
- NASA set for first crewed moon return in over half a century
- Exploiting Unsold Rams: May Be Less expensive Than You Suspect
- Novo Nordisk cuts Wegovy price as CEO pledges to go 'all in' on weight loss pill
- Public mistrust linked to drop in deceased donor organ donations and kidney transplants
- 10 Famous Frozen yogurt Flavors All over The Planet
- Scientists document a death from a meat allergy tied to certain ticks
- Home Plan Tips for Seniors
- Eleven arrested over mass shooting in South Africa tavern
